{
    "clinical_study": {
        "@rank": "26671", 
        "acronym": "Hydrus II", 
        "arm_group": [
            {
                "arm_group_label": "IOL placement with Hydrus Implant", 
                "arm_group_type": "Experimental", 
                "description": "Cataract extraction with intraocular lens (IOL) placement and Hydrus Implant"
            }, 
            {
                "arm_group_label": "IOL placement only.", 
                "arm_group_type": "Active Comparator", 
                "description": "Cataract Extraction with IOL placement only."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to demonstrate the ability of the Hydrus Implant to lower\n      intraocular pressure in glaucoma patients undergoing cataract surgery."
        }, 
        "brief_title": "Safety and Efficacy Trial to Evaluate the Hydrus(TM) Implant in Subjects Undergoing Cataract Surgery.", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Primary Open Angle Glaucoma", 
            "Glaucoma, Open Angle, Pseudo-exfoliative", 
            "Cataract Unilateral Pending Extraction"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Cataract"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a post-market, prospective, single-masked, randomized, controlled, multicenter\n      clinical trial comparing Cataract Extraction (CE) surgery + Hydrus Implant vs CE surgery\n      alone for the reduction of intraocular pressure (IOP) in patients with a positive diagnosis\n      for open angle glaucoma (POAG) or pseudoexfoliative glaucoma.  Eligible patients will be\n      scheduled for cataract surgery.  At the time of the procedure, qualified subjects will be\n      randomized into 1 of 2 treatment groups: Hydrus Implant with cataract surgery or cataract\n      surgery alone.  Post-operative follow up will be conducted at regular intervals."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of Primary Open Angle Glaucoma or Pseudoexfoliative Glaucoma.\n\n          -  Operable, age-related cataract eligible for phacoemulsification.\n\n        Exclusion Criteria:\n\n          -  Closed Angle and narrow angle forms of Glaucoma.\n\n          -  Other Secondary Glaucoma, (such as neovascular, uveitic, traumatic, steroid induced,\n             lens induced); glaucoma associated with increase episcleral venous pressure;\n             congenital or developmental glaucoma."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01818115", 
            "org_study_id": "CP-10-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "IOL placement with Hydrus Implant", 
                "intervention_name": "Hydrus Implant", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "IOL placement only.", 
                "intervention_name": "IOL placement", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "POAG", 
            "PXG", 
            "IOL Surgery", 
            "CE Surgery"
        ], 
        "lastchanged_date": "March 25, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany"
                    }, 
                    "name": "See Central Contact"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany"
                    }, 
                    "name": "See Central Contact"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Parma", 
                        "country": "Italy"
                    }, 
                    "name": "See Central Contact"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy"
                    }, 
                    "name": "See Central Contact"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "See Central Contact"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "See Central Contact"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zaragoza", 
                        "country": "Spain"
                    }, 
                    "name": "See Central Contact"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Italy", 
                "Netherlands", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Multi-Center, Randomized Controlled Trial to Evaluate the Safety and Effectiveness of the Hydrus Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery.", 
        "overall_official": {
            "affiliation": "Universitatsmedizin Mainz", 
            "last_name": "Prof. Norbert Pfeiffer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A 24 month visit will be conducted to confirm 12 month findings.", 
            "measure": "Reduction in mean diurnal Intraocular Pressure (IOP) at 12 months following the wash-out of all glaucoma medications.", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01818115"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "A 24 month visit will be conducted to confirm 12 month findings.", 
                "measure": "The proportion of eyes with reduction in washed out IOP of at least 20% from baseline to 12 months.", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "A 24 month visit will be conducted to confirm 12 month findings.", 
                "measure": "Change in Best-corrected Visual Acuity (BCVA) from baseline to 12 months as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart.", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "A 24 month visit will be conducted to confirm 12 month findings.", 
                "measure": "The proportion of eyes with IOP >5 mmHg to \u226419 mmHg following terminal washout.", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "A 24 month visit will be conducted to confirm 12 month findings", 
                "measure": "Diurnal IOP at 24 months following washout", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Ivantis, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ivantis, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}